Problems in salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones.

Abstract

Disease syndromes caused by Salmonella species continue to be important, as evidenced by a major outbreak of infection due to multiresistant Salmonella typhimurium in 1985; this outbreak involved more than 12,000 people in five north-central states of the United States. Salmonella species have become progressively more resistant in recent years to the clinically useful antibiotics (trimethoprim-sulfamethoxazole, ampicillin, and chloramphenicol). The clinical experience accumulated thus far indicates that two new classes of antimicrobial agents, the third-generation cephalosporins and the quinolones, offer significant potential for the treatment of specific problems in salmonellosis: bacteremia and enteric fever, meningitis, osteomyelitis, and the chronic carrier state.

• Authors: J P Bryan, H Rocha, W M Scheld
• Journal: Reviews of infectious diseases (Rev Infect Dis) 1986 Mar-Apr Vol. 8 Issue 2 Pg. 189-207 ISSN: 0162-0886 [Print] United States
• PMID: 3518021 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• Drug Combinations
• Quinolines
• Chloramphenicol
• Ampicillin
• Trimethoprim, Sulfamethoxazole Drug Combination
• Trimethoprim
• Sulfamethoxazole

Topics

• Ampicillin (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Carrier State (drug therapy)
• Cephalosporins (therapeutic use)
• Chloramphenicol (therapeutic use)
• Cholecystectomy
• Chronic Disease
• Clinical Trials as Topic
• Drug Combinations (therapeutic use)
• Humans
• Meningitis (drug therapy)
• Microbial Sensitivity Tests
• Osteomyelitis (drug therapy)
• Penicillin Resistance
• Quinolines (therapeutic use)
• Salmonella Infections (drug therapy)
• Sepsis (drug therapy)
• Sulfamethoxazole (therapeutic use)
• Trimethoprim (therapeutic use)
• Trimethoprim, Sulfamethoxazole Drug Combination
• Typhoid Fever (drug therapy)